Press Releases

Veterinarians have been using polymerase chain reaction for antigen receptor rearrangement (PARR), a readily available molecular assay that helps diagnose some kinds of canine lymphoma, for years.

In a study published in the Journal of Veterinary Internal Medicine (JVIM), Ethos and TGen found that their test, called ePARR, was more than 90 percent accurate among a range of lymphoma sample types. TGen conducted genetic analysis of more than 180 dogs with naturally occurring cancer to confirm if they had lymphoma, and then determine exactly what type of lymphoma, which is a common and aggressive cancer in dogs.

Hemangiosarcoma is one of the most malignant forms of cancer in dogs and CHAMP is the first nationwide, multicenter, prospective study of canine splenic hemangiosarcoma, which is a cancer of the blood vessels often affecting the spleen.

First-Ever Human Health and Animal Health Drug Development Collaboration to Prevent Cancer Recurrence. Ethos Veterinary Health and Vuja De Sciences to utilize novel cellular assays of cancer metastasis and integration of pet dogs with cancer to empower innovative metastasis-focused drug development collaboration.

Animal Clinical Investigation (ACI) and Ethos Veterinary Health (Ethos) have formed a strategic alliance offering a new mechanism to deliver market approval of pharmaceuticals and therapeutics in Animal Health. This relationship offers a unique opportunity for collaboration with organizations in the pharmaceutical industry, diagnostic developers and medical device companies.

Samsung plans to extend the number of new testing analytes for In-Vitro Diagnostic (IVD) devices and also add veterinary products for imaging devices such as ultrasound system to establish a total solution for pet healthcare market which is likely to show a sustainable growth.